CLINICAL_TRIALS
trial_result
· 2016-02-22
Clinical Trial Update: 38 Week Extension Study to CAIN457C2303 [Phase 3]
Summary
Novartis-sponsored Phase 3 extension study CAIN457C2303 for uveitis was terminated; results were posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Uveitis | Phase 3 | Status: TERMINATED | Results posted: 2016-02-22